US 9,168,314 B2Granted

Human antibody drug conjugates against tissue factor

AssigneeGenmab A/S

InventorsDavid Satijn, Sandra Verploegen, Wim Bleeker, Steen Lisby, Jan Van De Winkel, Patrick Van Berkel, Paul Parren

Life of this patent

Estimating the term…

Abstract

Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

Claims11

Dependent claims

An antibody drug conjugate comprising an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

(i) the VH region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
6, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
7, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
8, and the VL region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
46, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
47, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
48,
(ii) the VH region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
34, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
35, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
36, and the VL region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
74, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
75, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
76,
(iii) the VH region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
38, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
39, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
40, and the VL region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
78, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
79, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
80, or
(iv) the VH region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
2, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
3, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
4, and the VL region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
42, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
43, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
44,
wherein the antibody has been conjugated to an auristatin or a functional peptide analog or derivate thereof via a linker.

26 more elements

Dependencies are inferred from the claim text.

Facts

Application: 13/704,388Filed 15 Jun 2011 · us provisional application
Priority: DK PA 20100052915 Jun 2010
Published: US 2013/0101608 A125 Apr 2013
Granted: 27 Oct 2015
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61K 47/6817
The drug being a protein or peptide, e.g. transferrin or bleomycin: toxins
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…

Family

Application61/354,970Us provisional application · filed 15 Jun 2010
Application61/434,776Us provisional application · filed 20 Jan 2011
US 2013/0101608 A1Pre-grant publication · published 25 Apr 2013
US 9,168,314 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

An antibody drug conjugate comprising an antibody comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein:

(i) the VH region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
6, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
7, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
8, and the VL region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
46, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
47, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
48,
(ii) the VH region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
34, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
35, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
36, and the VL region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
74, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
75, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
76,
(iii) the VH region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
38, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
39, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
40, and the VL region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
78, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
79, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
80, or
(iv) the VH region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
2, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
3, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
4, and the VL region comprises a CDR1 comprising the amino acid sequence set forth in SEQ ID NO:
42, a CDR2 comprising the amino acid sequence set forth in SEQ ID NO:
43, and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO:
44,
wherein the antibody has been conjugated to an auristatin or a functional peptide analog or derivate thereof via a linker.

26 more elements

Facts

Application

13/704,388Filed 15 Jun 2011 · us provisional application

Priority

DK PA 20100052915 Jun 2010

Published

US 2013/0101608 A125 Apr 2013

Granted

27 Oct 2015

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61K 47/6817
The drug being a protein or peptide, e.g. transferrin or bleomycin: toxins
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…